Prolonged presence of SARS-CoV-2 in a COVID-19 case with rheumatoid arthritis taking iguratimod treated with ciclesonide. Issue 10 (October 2020)

• Record Type: Journal Article
• Authors: Baba, Hiroaki; Kanamori, Hajime; Oshima, Kengo; Seike, Issei; Niitsuma-Sugaya, Ikumi; Takei, Kentaro; Sato, Yukio; Tokuda, Koichi; Aoyagi, Tetsuji
• Is Part Of: Journal of infection and chemotherapy. Volume 26:Issue 10(2020:Oct.)
• Page Start: 1100
• Page End: 1103
• Publication Date: 2020-10
• Subjects: Coronavirus disease 2019 -- Iguratimod -- Ciclesonide -- Viral shedding; COVID-19 coronavirus disease 2019 -- SARS-CoV-2 severe acute respiratory syndrome coronavirus 2 -- DMARDs disease-modifying antirheumatic drugs -- RT-PCR reverse transcription polymerase chain reaction -- CRP C-reactive protein -- SARS severe acute respiratory syndrome -- MERS Middle East respiratory syndrome; Chemotherapy -- Periodicals; Infection -- Periodicals; Communicable diseases -- Chemotherapy -- Periodicals; 615.5805
• DOI: 10.1016/j.jiac.2020.06.022
• Languages: English
• ISSNs: 1341-321X

Abstract

Abstract: We report a coronavirus disease 2019 (COVID-19) case with rheumatoid arthritis taking iguratimod. The patient who continued iguratimod therapy without dose reduction was treated with ciclesonide had an uneventful clinical course, but prolonged detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was observed after resolution of symptoms. The effects of disease-modifying antirheumatic drugs (DMARDs) and ciclesonide on clinical course and viral shedding remain unknown and warrant further investigation.